Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Entelos Inc., Iconix deal

ENTL acquired Iconix for 12.8 million shares valued at £4.2

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE